...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part II: effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs.
【24h】

HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part II: effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs.

机译:HMR 1883,ATP敏感钾通道的新型心脏选择性抑制剂。第二部分:清醒犬对心肌缺血引起的心室颤动敏感性的影响。

获取原文
获取原文并翻译 | 示例

摘要

The activation of the ATP-sensitive potassium channel (KATP) during myocardial ischemia leads to potassium efflux, reductions in action potential duration and the formation of ventricular fibrillation (VF). Drugs that inactivate KATP should prevent these changes and thereby prevent VF. However, most KATP antagonists also alter pancreatic channels, which promote insulin release and hypoglycemia. Recently, a cardioselective KATP antagonist, HMR 1883, has been developed that may offer cardioprotection without the untoward side effects of existing compounds. Therefore, VF was induced in 13 mongrel dogs with healed myocardial infarctions by a 2-min coronary artery occlusion during the last minute of a submaximal exercise test. On subsequent days, the exercise-plus-ischemia test was repeated after pretreatment with HMR 1883 (3.0 mg/kg i.v., n = 13) or glibenclamide (1.0 mg/kg i.v., n = 7). HMR 1883 (P < .001) and glibenclamide (P < .01) prevented VF in 11 of 13 and 6 of 7 animals, respectively. Glibenclamide, but not HMR 1883, elicited increases in plasma insulin and reductions in blood glucose. Glibenclamide also reduced (P < .01) both mean coronary blood flow and left ventricular dP/dt maximum as well as the reactive hyperemia induced by 15-sec coronary occlusions (-30.3 +/- 11%), whereas HMR 1883 did not alter this increase in coronary flow (-3.0 +/- 4.7%). Finally, myocardial ischemia (n = 10) significantly (P < .01) reduced refractory period (control, 121 +/- 2 msec; occlusion, 115 +/- 2 msec), which was prevented by either glibenclamide or HMR 1883. Thus, the cardioselective KATP antagonist HMR 1883 can prevent ischemically induced reductions in refractory period and VF without major hemodynamic effects or alterations in blood glucose levels. These data further suggest that the activation of KATPs may play a particularly important role in both the reductions in refractory period and lethal arrhythmia formation associated with myocardial ischemia.
机译:心肌缺血期间ATP敏感性钾通道(KATP)的激活导致钾外排,动作电位持续时间的减少和心室纤颤(VF)的形成。使KATP失活的药物应防止这些变化,从而预防VF。但是,大多数KATP拮抗剂也会改变胰腺通道,从而促进胰岛素释放和低血糖症。最近,已开发出一种心脏选择性KATP拮抗剂HMR 1883,它可以提供心脏保护作用,而不会产生现有化合物的不良副作用。因此,在次最大运动测试的最后一分钟,通过2分钟的冠状动脉闭塞,在13例患有心肌梗塞的杂种狗中诱发了VF。在随后的几天中,在用HMR 1883(3.0 mg / kg i.v.,n = 13)或格列本脲(1.0 mg / kg i.v.,n = 7)进行预处理后,重复进行运动加缺血试验。 HMR 1883(P <.001)和格列本脲(P <.01)分别预防​​了13只中的11只和7只中的6只的VF。格列本脲而不是HMR 1883引起血浆胰岛素增加和血糖降低。格列本脲也降低了平均冠状动脉血流量和左心室dP / dt最大值以及15秒冠状动脉闭塞引起的反应性充血(-30.3 +/- 11%)(P <.01),而HMR 1883并未改变冠状动脉血流量增加(-3.0 +/- 4.7%)。最后,心肌缺血(n = 10)显着(P <.01)减少了不应期(对照组,121 +/- 2毫秒;阻塞,115 +/- 2毫秒),这可以通过格列本脲或HMR 1883来预防。 ,心脏选择性KATP拮抗剂HMR 1883可以防止难治期和VF的化学诱导诱导的减少,而没有主要的血液动力学影响或血糖水平的改变。这些数据进一步表明,KATPs的激活可能在不应期的减少和与心肌缺血相关的致死性心律失常的形成中起着特别重要的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号